The recently published INDIGO trial demonstrated that vorasidenib, an inhibitor of mutant isocitrate dehydrogenase 1 and 2 (IDH1/2), significantly improved progression-free survival compared to placebo in patients with low-grade IDH-mutant gliomas [44]. Here, IDH1 is linked to central nervous system cancer.